Septic shock: Treating more than just blood pressure

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 3, 2000, Pages 369-370

  Mayers, Irvin ^a   Johnson, David ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; M PROTEIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE; CYTOKINE RELEASE; HUMAN; PATHOGENESIS; SEPTIC SHOCK; SHORT SURVEY; TREATMENT FAILURE;

EID: 0034620552     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Wong DT, Gomez M, McGuire GP, Kavanagh B. Utilization of intensive care unit days in a Canadian medical-surgical intensive care unit. Crit Care Med 1999;27:1319-24.
2. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.
3. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methyl-prednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92:1032-6.
4. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-8.
5. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with tumor necrosis factor receptor:fc fusion protein. N Engl J Med 1996;334:1697-702.